Nalaganje...
Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
BACKGROUND: Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing regimens. However, no clinical trials have directly compared...
Shranjeno v:
| izdano v: | Chin J Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4845336/ https://ncbi.nlm.nih.gov/pubmed/27112139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0101-7 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|